Changing from Ozempic to Wegovy: the decision explained

Why the two products are not interchangeable, even though the molecule is the same

It is easy to assume that swapping Ozempic for Wegovy is a straightforward product change. The active ingredient is the same — semaglutide — but the similarities stop there. Ozempic is licensed in the UK for glycaemic control in adults with type 2 diabetes. Wegovy is licensed for weight management in adults with a BMI of 30 or above, or 27 or above where a weight-related condition such as high blood pressure or sleep apnoea is present. The dosing ladders differ too. Wegovy's titration climbs to a 2.4mg weekly maintenance dose, and since April 2026 a dedicated 7.2mg pen has been approved by the MHRA for adults with obesity, extending the maintenance ceiling further still. Ozempic's highest dose is 2mg, which is below Wegovy's standard endpoint. That gap matters for anyone switching specifically to access the weight-loss licence and its higher therapeutic ceiling.

The NHS medicines guidance on semaglutide sets out both products clearly, and it is worth reading so you understand what you are asking your prescriber to do. A switch is not simply a reissue of a similar product, it is a new prescription decision, with a new clinical rationale. If you have been reading about people changing from Ozempic to Wegovy and wondering whether it applies to you, that page goes deeper on the eligibility question specifically.

What your prescriber weighs up before agreeing to the switch

The decision your prescriber is making is genuinely complex. First, they need to understand why you were on Ozempic. If it was prescribed for type 2 diabetes, moving to Wegovy removes a licensed diabetes treatment and needs careful thought, particularly if you have no alternative diabetes management in place. Second, they will look at your current semaglutide dose. Someone who has been tolerating 1mg Ozempic weekly does not necessarily restart Wegovy from 0.25mg; the titration position is part of the clinical conversation, and the prescriber decides, not the patient. Third, they check for interactions, comorbidities and any other prescriptions that might affect the plan.

There is a practical timing consideration too. If your Ozempic supply runs to the end of the month and your finances or schedule mean you are planning around payday or a Monday order, that is worth flagging to whoever is managing the switch, so there is no accidental gap in treatment. Gaps in semaglutide use can affect tolerability when restarting. Our semaglutide overview covers what both products share clinically, which is useful background reading before your consultation.

One other practical note: demand for Wegovy has fluctuated since its UK launch, and availability of specific doses can vary by provider. The current state of Wegovy supply in the UK is something to check at the point you want to start, not just the point you decide to switch.

If you are also considering the direction of change, Wegovy back to Ozempic

Some people find themselves considering changing from Wegovy to Ozempic, either because of cost, because a diabetes diagnosis has emerged, or because their GP wants them on the diabetes-licensed product. The clinical logic runs in reverse here. A prescriber moving someone from Wegovy's weight-management dose to Ozempic is stepping down the available dose ceiling and changing the clinical rationale. It is still a prescription decision; neither switch is something a patient can manage unilaterally by adjusting what they order. The same principle applies if you are reading about the clinical mechanics of the Ozempic-to-Wegovy move more generally.

If a prescriber decides semaglutide is not the right option for you at all, there is a separate route worth knowing about. Tirzepatide (Mounjaro) is a dual GIP and GLP-1 receptor agonist, the only one of its kind licensed for weight management in the UK, and in the SURMOUNT-5 head-to-head trial published in the New England Journal of Medicine in 2025 it produced greater average weight loss than semaglutide 2.4mg over 72 weeks. NICE recommends it for adults with a BMI of 35 or above and at least one weight-related comorbidity, with lower thresholds for some ethnic backgrounds. It is a different clinical tool, not a fallback, but it is the comparison most clinicians consider if one semaglutide product is not working or not appropriate.

What is actually licensed for weight loss in the UK, and where nume fits

To be direct: Ozempic is not licensed for weight loss in the UK. Using it for that purpose is off-label, and that matters both clinically and practically. The two products with a full UK weight-management licence are Wegovy (semaglutide, by Novo Nordisk) and Mounjaro (tirzepatide, by Eli Lilly). These are the medicines a regulated UK prescriber will consider when weight management is the clinical goal. You can explore both on the weight-loss treatments overview.

nume is a GPhC-registered online pharmacy (registration number 9012878, verifiable at the GPhC register) dispensing Wegovy and Mounjaro for eligible adults. We do not dispense Ozempic for weight management. Every consultation is read and decided by a GPhC-registered Independent Prescriber, a named clinician, not a decision tree. The prescriber will consider your history, your current treatment if any, and which licensed option suits your circumstances. If you are thinking about where to access Wegovy through a regulated private pharmacy, the Wegovy sourcing guide covers what to look for and the red flags to avoid. For the cost side of the picture, the Wegovy treatment page sets out what private prescription pricing typically looks like and what is included.

If you are ready to talk to a prescriber about your options, the right starting point is a free consultation. Check your eligibility and speak to our clinical team at the consultation page.